PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070549
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2070549
Dual Incretin Agonists Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of dual incretin agonists Market
The global dual incretin agonists market was valued at USD 36.51 billion in 2025 and is projected to grow from USD 47.23 billion in 2026 to USD 85.80 billion by 2034, registering a CAGR of 7.75% during the forecast period. North America dominated the market in 2025, accounting for 59.57% of the global revenue share.
Dual incretin agonists are advanced therapies that target two metabolic hormone pathways simultaneously, helping patients achieve better blood glucose control and significant weight reduction. These therapies are increasingly used in the treatment of type 2 diabetes, obesity, and other cardiometabolic disorders. Rising prevalence of metabolic diseases, growing physician confidence in dual-action treatments, and expanding regulatory approvals are contributing significantly to market growth. Pharmaceutical companies are also investing heavily in clinical trials, label expansions, manufacturing capacity, and patient access programs.
Key Market Trends
One of the most significant trends shaping the market is the growing preference for dual-action metabolic therapies. Healthcare providers are increasingly adopting treatments capable of delivering comprehensive metabolic benefits, including glycemic control, weight loss, and cardiovascular improvements.
In November 2025, Eli Lilly and Company announced an agreement with the U.S. government to improve patient access to obesity medicines, highlighting the growing acceptance and demand for advanced dual incretin therapies.
Market Drivers
Rising Burden of Obesity and Type 2 Diabetes
The increasing global prevalence of obesity and diabetes is creating strong demand for therapies that address multiple metabolic conditions simultaneously. Dual incretin agonists provide effective blood sugar management while supporting significant weight reduction.
In October 2025, Innovent Biologics reported positive Phase III results for mazdutide, demonstrating superior glycemic control and weight loss compared to semaglutide, further validating the therapeutic potential of this drug class.
Market Restraints
High Treatment Costs and Reimbursement Challenges
Despite strong clinical benefits, the high cost of therapy remains a major barrier. Limited reimbursement coverage, prior authorization requirements, and high out-of-pocket expenses restrict patient access in several healthcare systems.
For example, NHS England introduced phased access to tirzepatide in March 2025, limiting initial prescribing to prioritized patient groups due to funding and service capacity constraints.
Market Opportunities
Expansion into Obesity and MASH/NASH Treatment
Significant opportunities exist as dual incretin agonists move beyond diabetes management into obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH).
In February 2024, Boehringer Ingelheim announced encouraging Phase II results for survodutide in MASH treatment, where up to 83% of patients showed clinical improvement.
Market Challenges
Manufacturing Capacity and Global Access
Demand for dual incretin therapies is rising faster than manufacturing capabilities. Companies must increase production capacity while simultaneously improving reimbursement and market access.
In June 2024, Eli Lilly and Company expanded its Indiana manufacturing facility with a USD 9 billion investment to boost production of tirzepatide and future metabolic therapies.
Segmentation Analysis
By Drug
Tirzepatide dominated the market in 2025 due to its strong commercial presence, broad clinical validation, and expanding indications across obesity and diabetes treatment.
The others segment is expected to register the fastest growth with a CAGR of 21.43% through the forecast period.
By Disease Indication
Type 2 diabetes accounted for the largest market share in 2025 due to early adoption and extensive physician acceptance.
The MASH/NASH segment is projected to expand at a CAGR of 22.49%, making it one of the fastest-growing applications.
By Age Group
The adult segment dominated the market due to a larger patient population and broader regulatory approvals.
The pediatric segment is expected to grow at a CAGR of 22.00%, supported by ongoing clinical development.
By Type
Branded products accounted for the majority of revenue in 2025 because leading dual incretin therapies remain protected by patents and face minimal generic competition.
By Route of Administration
The subcutaneous segment led the market owing to the commercial success of injectable therapies such as tirzepatide.
By Distribution Channel
Online pharmacies dominated due to increasing patient preference for digital ordering, home delivery, and manufacturer-supported access platforms.
Regional Analysis
North America
North America remained the largest regional market, reaching USD 21.75 billion in 2025. High obesity prevalence, strong healthcare infrastructure, and rapid adoption of innovative metabolic therapies continue to drive growth.
The U.S. market is estimated at USD 24.74 billion in 2026, representing approximately 52.38% of global revenue.
Europe
Europe is projected to reach USD 9.30 billion in 2026, supported by increasing regulatory approvals and physician adoption.
- United Kingdom: USD 1.27 billion (2026)
- Germany: USD 1.66 billion (2026)
Asia Pacific
Asia Pacific is forecast to reach USD 7.37 billion in 2026, driven by a growing diabetic population and expanding product availability.
- China: USD 2.06 billion (2026)
- Japan: USD 1.64 billion (2026)
- India: USD 0.81 billion (2026)
Latin America and Middle East & Africa
These regions are expected to witness steady growth due to increasing awareness of obesity management and expanding healthcare access.
- Latin America: USD 1.76 billion (2026)
- GCC: USD 0.54 billion (2026)
- South Africa: USD 0.27 billion (2026)
Competitive Landscape
The market is highly consolidated and led by major pharmaceutical companies investing heavily in clinical development, manufacturing expansion, and strategic partnerships.
Key companies operating in the market include:
- Eli Lilly and Company
- Innovent Biologics, Inc.
- Boehringer Ingelheim International GmbH
- Zealand Pharma A/S
- Hanmi Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- Altimmune, Inc.
- Viking Therapeutics, Inc.
- OPKO Health, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Recent Industry Developments
- September 2025: Pfizer acquired Metsera to strengthen its obesity and cardiometabolic portfolio.
- August 2025: Viking Therapeutics reported positive Phase II results for oral VK2735.
- July 2025: Hengrui Medicine announced successful Phase III results for HRS9531 in obesity treatment.
- June 2025: Altimmune reported positive Phase IIb results for pemvidutide in MASH.
- March 2025: Roche partnered with Zealand Pharma to co-develop petrelintide and CT-388 combination therapies.
Conclusion
The dual incretin agonists market is entering a phase of rapid expansion as healthcare systems increasingly focus on integrated management of obesity, type 2 diabetes, and cardiometabolic disorders. Valued at USD 36.51 billion in 2025, the market is expected to reach USD 47.23 billion in 2026 and further expand to USD 85.80 billion by 2034. Strong clinical outcomes, growing physician adoption, expanding indications, and continued investments by leading pharmaceutical companies are expected to drive long-term growth. Although high treatment costs and manufacturing scalability remain challenges, ongoing innovation and broader patient access initiatives are likely to strengthen market penetration and create substantial opportunities throughout the forecast period.
Segmentation By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region
By Drug * Tirzepatide
- Survodutide
- Others
By Disease Indication * Type 2 Diabetes
- Obesity
- MASH/NASH
- Others
By Age Group * Pediatric
- Adults
By Type * Branded
- Generic
By Route of Administration * Subcutaneous
- Oral
- Others
By Distribution Channel * Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
By Region * North America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Disease Indications, By Key Regions/ Countries
- 4.2. New Product Launches, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
- 4.5. Pipeline Analysis, By Key Players
5. Global Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Tirzepatide
- 5.1.2. Survodutide
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. Type 2 Diabetes
- 5.2.2. Obesity
- 5.2.3. MASH/NASH
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Generics
- 5.5. Market Analysis, Insights and Forecast - By Route of Administration
- 5.5.1. Subcutaneous
- 5.5.2. Oral
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.6.1. Hospital Pharmacies
- 5.6.2. Drug Stores & Retail Pharmacies
- 5.6.3. Specialty Pharmacies
- 5.6.4. Online Pharmacies
- 5.7. Market Analysis, Insights and Forecast - Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
6. North America Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Tirzepatide
- 6.1.2. Survodutide
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. Type 2 Diabetes
- 6.2.2. Obesity
- 6.2.3. MASH/NASH
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Generics
- 6.5. Market Analysis, Insights and Forecast - By Route of Administration
- 6.5.1. Subcutaneous
- 6.5.2. Oral
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.6.1. Hospital Pharmacies
- 6.6.2. Drug Stores & Retail Pharmacies
- 6.6.3. Specialty Pharmacies
- 6.6.4. Online Pharmacies
- 6.7. Market Analysis, Insights and Forecast - By Country
- 6.7.1. U.S.
- 6.7.2. Canada
7. Europe Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Tirzepatide
- 7.1.2. Survodutide
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. Type 2 Diabetes
- 7.2.2. Obesity
- 7.2.3. MASH/NASH
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Generics
- 7.5. Market Analysis, Insights and Forecast - By Route of Administration
- 7.5.1. Subcutaneous
- 7.5.2. Oral
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.6.1. Hospital Pharmacies
- 7.6.2. Drug Stores & Retail Pharmacies
- 7.6.3. Specialty Pharmacies
- 7.6.4. Online Pharmacies
- 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.7.1. U.K.
- 7.7.2. Germany
- 7.7.3. France
- 7.7.4. Italy
- 7.7.5. Spain
- 7.7.6. Scandinavia
- 7.7.7. Rest of Europe
8. Asia Pacific Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Tirzepatide
- 8.1.2. Survodutide
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. Type 2 Diabetes
- 8.2.2. Obesity
- 8.2.3. MASH/NASH
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Generics
- 8.5. Market Analysis, Insights and Forecast - By Route of Administration
- 8.5.1. Subcutaneous
- 8.5.2. Oral
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.6.1. Hospital Pharmacies
- 8.6.2. Drug Stores & Retail Pharmacies
- 8.6.3. Specialty Pharmacies
- 8.6.4. Online Pharmacies
- 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.7.1. China
- 8.7.2. Japan
- 8.7.3. India
- 8.7.4. Southeast Asia
- 8.7.5. Australia
- 8.7.6. Rest of Asia Pacific
9. Latin America Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Tirzepatide
- 9.1.2. Survodutide
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. Type 2 Diabetes
- 9.2.2. Obesity
- 9.2.3. MASH/NASH
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Generics
- 9.5. Market Analysis, Insights and Forecast - By Route of Administration
- 9.5.1. Subcutaneous
- 9.5.2. Oral
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.6.1. Hospital Pharmacies
- 9.6.2. Drug Stores & Retail Pharmacies
- 9.6.3. Specialty Pharmacies
- 9.6.4. Online Pharmacies
- 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.7.1. Brazil
- 9.7.2. Mexico
- 9.7.3. Rest of Latin America
10. Middle East & Africa Dual Incretin Agonists Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug
- 10.1.1. Tirzepatide
- 10.1.2. Survodutide
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. Type 2 Diabetes
- 10.2.2. Obesity
- 10.2.3. MASH/NASH
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Generics
- 10.5. Market Analysis, Insights and Forecast - By Route of Administration
- 10.5.1. Subcutaneous
- 10.5.2. Oral
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.6.1. Hospital Pharmacies
- 10.6.2. Drug Stores & Retail Pharmacies
- 10.6.3. Specialty Pharmacies
- 10.6.4. Online Pharmacies
- 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.7.1. GCC
- 10.7.2. South Africa
- 10.7.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Eli Lilly and Company
- 11.2.2. Innovent Biologics, Inc.
- 11.2.3. Boehringer Ingelheim International GmbH
- 11.2.4. Zealand Pharma A/S
- 11.2.5. Hanmi Pharmaceutical Co., Ltd.
- 11.2.6. Merck & Co., Inc.
- 11.2.7. Altimmune, Inc.
- 11.2.8. Viking Therapeutics, Inc.
- 11.2.9. OPKO Health, Inc.
- 11.2.10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
List of Tables
- Figure 1: Global Dual Incretin Agonists Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Dual Incretin Agonists Market Value Share (%), by Drug, 2025 & 2034
- Figure 3: Global Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025 & 2034
- Figure 4: Global Dual Incretin Agonists Market Value Share (%), by Age Group, 2025 & 2034
- Figure 5: Global Dual Incretin Agonists Market Value Share (%), by Type, 2025 & 2034
- Figure 6: Global Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 7: Global Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 8: Global Dual Incretin Agonists Market Value Share (%), by Region, 2025 & 2034
- Figure 9: North America Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
- Figure 10: North America Dual Incretin Agonists Market Value Share (%), by Drug, 2025
- Figure 11: North America Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 12: North America Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
- Figure 13: North America Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 14: North America Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
- Figure 15: North America Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
- Figure 16: North America Dual Incretin Agonists Market Value Share (%), by Type, 2025
- Figure 17: North America Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 18: North America Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
- Figure 19: North America Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 20: North America Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
- Figure 21: North America Dual Incretin Agonists Market Value (USD billion), by Country, 2025 & 2034
- Figure 22: North America Dual Incretin Agonists Market Value Share (%), by Country, 2025
- Figure 23: Europe Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
- Figure 24: Europe Dual Incretin Agonists Market Value Share (%), by Drug, 2025
- Figure 25: Europe Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 26: Europe Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
- Figure 27: Europe Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 28: Europe Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
- Figure 29: Europe Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
- Figure 30: Europe Dual Incretin Agonists Market Value Share (%), by Type, 2025
- Figure 31: Europe Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 32: Europe Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
- Figure 33: Europe Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Europe Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Europe Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 36: Europe Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
- Figure 37: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
- Figure 38: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Drug, 2025
- Figure 39: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 40: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
- Figure 41: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 42: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
- Figure 43: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
- Figure 44: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Type, 2025
- Figure 45: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 46: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
- Figure 47: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 48: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
- Figure 49: Asia Pacific Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 50: Asia Pacific Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
- Figure 51: Latin America Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
- Figure 52: Latin America Dual Incretin Agonists Market Value Share (%), by Drug, 2025
- Figure 53: Latin America Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 54: Latin America Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
- Figure 55: Latin America Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 56: Latin America Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
- Figure 57: Latin America Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
- Figure 58: Latin America Dual Incretin Agonists Market Value Share (%), by Type, 2025
- Figure 59: Latin America Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 60: Latin America Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
- Figure 61: Latin America Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 62: Latin America Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
- Figure 63: Latin America Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 64: Latin America Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
- Figure 65: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Drug, 2025 & 2034
- Figure 66: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Drug, 2025
- Figure 67: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 68: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Disease Indication, 2025
- Figure 69: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 70: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Age Group, 2025
- Figure 71: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Type, 2025 & 2034
- Figure 72: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Type, 2025
- Figure 73: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 74: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Route of Administration, 2025
- Figure 75: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 76: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Distribution Channel, 2025
- Figure 77: Middle East & Africa Dual Incretin Agonists Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 78: Middle East & Africa Dual Incretin Agonists Market Value Share (%), by Country/ Sub-region, 2025
- Figure 79: Global Dual Incretin Agonists Market Share (%), by Company, 2025
